VolitionRx Limited (NYSEAMERICAN:VNRX) Sees Large Increase in Short Interest

by · The Cerbat Gem

VolitionRx Limited (NYSEAMERICAN:VNRX – Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 690,600 shares, an increase of 36.1% from the March 15th total of 507,400 shares. Currently, 1.3% of the company’s shares are sold short. Based on an average trading volume of 155,200 shares, the short-interest ratio is presently 4.4 days.

VolitionRx Stock Down 2.0 %

Shares of NYSEAMERICAN:VNRX traded down $0.01 during midday trading on Friday, hitting $0.49. The company had a trading volume of 169,558 shares, compared to its average volume of 159,791. VolitionRx has a 12 month low of $0.42 and a 12 month high of $1.02. The firm has a market capitalization of $30.96 million, a P/E ratio of -0.87 and a beta of 1.59.

About VolitionRx

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

Read More